Trial · NCT02252263
Registered outcomes21
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
1 to 20 of 21
Download this page as JSON| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Safety as measured by the rate of AEs, SAEs, deaths is the primary endpoint of this Phase 1 study. All subjects who receive at least one (full or partial) dose of Elotuzumab, Lirilumab or Urelumab will be evaluated for safety | During treatment and first 100 days after treatment | adverse events (AEs), serious adverse events (SAEs) |
| Secondary | Best Overall Response (BOR) | At different timepoints approximately up to 2.5 years | |
| Secondary | Objective Response rate (ORR) | At different timepoints approximately up to 2.5 years | |
| Secondary | Median Duration of Response (mDOR) | At different timepoints approximately up to 2.5 years | |
| Secondary | Median Time to Response (mTTR) | At different timepoints approximately up to 2.5 years | |
| Secondary | Progression-free survival rate (PFSR) | At different timepoints approximately up to 2.5 years | |
| Secondary | M-protein levels | At different timepoints approximately up to 2.5 years | |
| Secondary | Minimal Residual Disease (MRD) status for Post Autologous Transplant subjects | At different timepoints approximately up to 2.5 years | |
| Secondary | Maximum concentration of Urelumab (Cmax) | At different timepoints approximately up to 2.5 years | |
| Secondary | Maximum concentration of Lirilumab (Cmax) | At different timepoints approximately up to 2.5 years | |
| Secondary | Area under the Curve (AUCTAU) of Urelumab | At different timepoints approximately up to 2.5 years | |
| Secondary | Area under the Curve (AUCTAU) of Lirilumab | At different timepoints approximately up to 2.5 years | |
| Secondary | Volume of distribution (Vz) for Urelumab | At different timepoints approximately up to 2.5 years | |
| Secondary | Total Clearance (CLT) of Urelumab | At different timepoints approximately up to 2.5 years | |
| Secondary | Total Clearance (CLT) of Lirilumab | At different timepoints approximately up to 2.5 years | |
| Secondary | Concentration at the end of infusion (ceoinf) of Urelumab | At different timepoints approximately up to 2.5 years | |
| Secondary | Concentration at the end of infusion (ceoinf) of Elotuzumab | At different timepoints approximately up to 2.5 years | |
| Secondary | Concentration at the end of infusion (ceoinf) of Lirilumab | At different timepoints approximately up to 2.5 years | |
| Secondary | Cmin will be capture at steady state of all study subjects | At different timepoints approximately up to 2.5 years | |
| Secondary | Occurence of Specific anti-drug antibodies (ADA) to each study drug | At different timepoints approximately up to 2.5 years |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT02252263/registered